{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T20:30:00Z","timestamp":1778185800900,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T00:00:00Z","timestamp":1511308800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00198-017-4304-9","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T17:20:08Z","timestamp":1511371208000},"page":"323-328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial"],"prefix":"10.1007","volume":"29","author":[{"given":"J. P.","family":"Bilezikian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Hattersley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. A.","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. G.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Shevroja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Banks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. Z.","family":"Leder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. R.","family":"Zanchetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Hans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,22]]},"reference":[{"key":"4304_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1210\/en.2015-1726","volume":"157","author":"G Hattersley","year":"2016","unstructured":"Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ (2016) Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology 157:141\u2013149","journal-title":"Endocrinology"},{"key":"4304_CR2","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ et al (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis. JAMA 316:722\u2013733","journal-title":"JAMA"},{"key":"4304_CR3","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00198-014-2703-8","volume":"25","author":"C Senn","year":"2014","unstructured":"Senn C, Gunther B, Popp AW, Perrelet R, Hans D, Lippuner K (2014) Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study. Osteoporos Int 25:1945\u20131951","journal-title":"Osteoporos Int"},{"key":"4304_CR4","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1359\/jbmr.070413","volume":"22","author":"P Chen","year":"2007","unstructured":"Chen P, Miller PD, Recker R et al (2007) Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res 22:1173\u20131180","journal-title":"J Bone Miner Res"},{"key":"4304_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jbmr.3003","volume":"32","author":"A Varela","year":"2017","unstructured":"Varela A, Chouinard L, Lesage E, Smith SY, Hattersley G (2017) One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption. J Bone Miner Res 32:24\u201333","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"4304_CR6","first-page":"S18","volume":"29","author":"A Varela","year":"2014","unstructured":"Varela A, Haile S, Doyle N, Smith SY, Guldberg R, Hattersley G (2014) The long-term effects of abaloparatide (BA058) on micro-CT and histomorphometry in osteopenic cynomolgus monkeys. J Bone Miner Res 29(Suppl 1):S18","journal-title":"J Bone Miner Res"},{"key":"4304_CR7","first-page":"S319","volume":"29","author":"N Doyle","year":"2014","unstructured":"Doyle N, Varela A, Smith SY, Hattersley G (2014) Abaloparatide (BA058), a human PTHrP analog: correlation of in vivo bone mass gains and improved strength in the osteopenic cynomolgus monkey. J Bone Miner Res 29:S319","journal-title":"J Bone Miner Res"},{"key":"4304_CR8","unstructured":"Bahar H, Doyle N, Varela A, et al. (2015) Abaloparatide treatment increases bone formation without corresponding increases in bone resorption resulting in marked bone gains in osteopenic ovariectomized monkeys and rats. Endoc Rev 36:Abstract OR08\u20133"},{"key":"4304_CR9","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jocd.2011.05.005","volume":"14","author":"D Hans","year":"2011","unstructured":"Hans D, Barthe N, Boutroy S, Pothuaud L, Winzenrieth R, Krieg MA (2011) Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae. J Clin Densitom 14:302\u2013312","journal-title":"J Clin Densitom"},{"key":"4304_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.bone.2015.06.007","volume":"79","author":"C Muschitz","year":"2015","unstructured":"Muschitz C, Kocijan R, Haschka J et al (2015) TBS reflects trabecular microarchitecture in premenopausal women and men with idiopathic osteoporosis and low-traumatic fractures. Bone 79:259\u2013266","journal-title":"Bone"},{"key":"4304_CR11","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/jbmr.2176","volume":"29","author":"BC Silva","year":"2014","unstructured":"Silva BC, Leslie WD, Resch H et al (2014) Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res 29:518\u2013530","journal-title":"J Bone Miner Res"},{"key":"4304_CR12","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/jbmr.2734","volume":"31","author":"EV McCloskey","year":"2016","unstructured":"McCloskey EV, Od\u00e9n A, Harvey NC et al (2016) A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res 31:940\u2013948","journal-title":"J Bone Miner Res"},{"key":"4304_CR13","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1210\/jc.2014-3718","volume":"100","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, O\u2019Dea LS, Zanchetta JR et al (2015) Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 100:697\u2013706","journal-title":"J Clin Endocrinol Metab"},{"key":"4304_CR14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.bone.2015.05.016","volume":"78","author":"NC Harvey","year":"2015","unstructured":"Harvey NC, Gl\u00fcer CC, Binkley N et al (2015) Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone 78:216\u2013224","journal-title":"Bone"},{"key":"4304_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jocd.2015.06.008","volume":"18","author":"BC Silva","year":"2015","unstructured":"Silva BC, Broy SB, Boutroy S, Schousboe JT, Shepherd JA, Leslie WD (2015) Fracture risk prediction by non-BMD DXA measures: the 2015 ISCD official positions part 2: trabecular bone score. J Clin Densitom 18:309\u2013330","journal-title":"J Clin Densitom"},{"key":"4304_CR16","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jocd.2017.06.019","volume":"20","author":"E Shevroja","year":"2017","unstructured":"Shevroja E, Lamy O, Kohlmeier L, Koromani F, Rivadeneira F, Hans D (2017) Use of trabecular bone score (TBS) as a complementary approach to dual-energy x-ray absorptiometry (DXA) for fracture risk assessment in clinical practice. J Clin Densitom 20:334\u2013345","journal-title":"J Clin Densitom"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-017-4304-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-017-4304-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-017-4304-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T10:20:15Z","timestamp":1551176415000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-017-4304-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,22]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["4304"],"URL":"https:\/\/doi.org\/10.1007\/s00198-017-4304-9","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,22]]},"assertion":[{"value":"11 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JPB is a consultant for Radius Health, Inc., Shire, Amgen, Eli Lilly, and Ultragenyx.GH, LAF, AGH, are employees of Radius Health, Inc., and own company stock.KB is an employee of Radius Health, Inc.ES and JRZ have nothing to disclose.BZL has been a consultant for Merck, and has been a consultant for and received research funding from Amgen and Eli Lilly.DH is co-owner of the trabecular bone score (TBS) patent and is a part-time employee of Medimaps Group, and owns company stock.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All patients had provided informed written consent prior to their participation, in accordance with the Declaration of Helsinki for research on human subjects.ABL-SC, abaloparatide-SC; SEM, standard error of the mean; TBS, trabecular bone score; TPTD, teriparatide.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of informed consent"}}]}}